Regulatory/Agencies/SFDA
🇸🇦Saudi Food and Drug Authority

SFDA NAMs Framework

Saudi Arabia's SFDA is implementing Vision 2030 biotech strategy with NAMs pilot programs and KFSH research collaboration.

$3.9B
Biotech Investment
KFSH
Research Partner
2030
Vision Target
Pilot
Programs
Written by J Radler | Patient Analog
Last updated: January 2025

Regulatory Highlights

  • Current regulatory framework and acceptance pathways
  • Compliance requirements for NAMs submissions
  • International harmonization through ICH guidelines
  • Practical guidance for regulatory strategy

Vision 2030 Biotech Strategy

Saudi Arabia's Vision 2030 includes significant investment in biotechnology and pharmaceutical innovation, with NAMs playing a key role in modernizing the regulatory framework.

KFSH Research Partnership

King Faisal Specialist Hospital leads NAMs research in the region:

  • Organoid Development: Cancer and disease modeling programs
  • Clinical Translation: Bridging research to regulatory acceptance
  • Regional Training: Building NAMs expertise in the Gulf region

Related Agencies

🇦🇪 UAE MOH🇪🇺 EMA🇺🇸 FDA

© 2025 Patient Analog. All rights reserved.

Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.

Free to share for educational purposes with attribution.